Objective
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. Although conventional cancer chemotherapy can provide profound benefits, seriously adverse side-effects still cannot be avoided, due to lack of specific targeting nature of current treatments. Nanomedicine can reduce such side-effects by exploiting characteristic properties of tumors for targeted delivery and therapy. Despite extensive research, most nanomedicines developed so far have relied on passive targeting using a single therapeutic modality, which are inefficient for treatment of challenging conditions such as multi-drug resistance.
Recently we developed a pH-responsive-DNA-GNP conjugate based nanocarrier that numerous features required for an ideal drug nanocarrier, e.g. uniform small nanoscale size, resisting non-specific adsorption, non-toxic, biocompatible, water-soluble, stable, and having high drug loading and controlled release capacities. It can offer efficient and pH-triggered drug release suitable for effective cancer chemotherapy at the cellular level using doxorubicin, a widely used chemotherapy drug.
Herein we will extend it into a more effective, multifunctional nanomedicine that can offer simultaneous biomodal chemotherapies with hyperthermia and MRI imaging capacities. First, we will prepare, characterize, and evaluate their drug loading & release profiles in buffer; then we will study and quantify their cell- & cell-specific- uptake and drug delivery efficiency, and then evaluate their toxicity, cytotoxicity & cell-specific cytotoxicity with cancer cells (incoming phase), and finally evaluate their synergistic therapeutic efficacy at cellular and preclinical level (re-integration phase). This project will greatly benefit both the fundamental research in nanomedicine and the healthcare/pharmaceutical indurstries in Europe.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology nanomedicine
- medical and health sciences clinical medicine oncology
- engineering and technology nanotechnology nano-materials
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-IIF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
LS2 9JT Leeds
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.